Insmed
INSMInsmed is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases across three core therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare.
Earnings
Next report
Oct 29, 2026 (in 2 months)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Insmed is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases across three core therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The company's value proposition centers on its proprietary drug delivery technologies, such as Pulmovance liposomal delivery, and its ability to advance first-in-class treatments for chronic lung infections and inflammatory conditions.
Insmed holds a leading position in the NTM lung disease market with the only approved inhaled therapy in major regions and is a first-mover in the bronchiectasis space with the recent approval of BRINSUPRI.
FAQ
- What is Insmed's market cap?
- Insmed (INSM) has a market capitalization of $27.2B and trades on NASDAQ.
- What is Insmed's revenue and profitability?
- Insmed generated $1.1B in trailing twelve-month revenue with a net loss of $875.3M, representing a net margin of -76.9%. Gross margin stands at 83.5%, with free cash flow of -$807.7M. These figures are based on the Q2 2026 filing.
- Who are Insmed's competitors?
- Insmed's key competitors include United Therapeutics Corporation, Sarepta Therapeutics, Inc., Spero Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Insmed partner with?
- Insmed's notable partners include AstraZeneca, PARI Pharma GmbH, Thermo Fisher Scientific, Inc., and others.
- Where is Insmed headquartered?
- Insmed is headquartered in United States of America and employs approximately 912 people. It has been publicly traded since 2000.
